Four phrases that sell peptides, fact-checked — as Congress weighs promoting them for troops and veterans

Edited by Samael A. Tejada, Founder & Editor-in-Chief

Yesterday this site explained the new federal compounding policy in full. Today the other side of the ledger: the sales language that fills the gap where clinical trials should be, and a Congress being asked to promote the products before the evidence arrives.

What are the four phrases, and what is wrong with them?

KFF Health News singles out four. (1) 'Peptides are not drugs' — they are short amino-acid chains that tell cells and organs what to do, which is precisely what a drug is; approved peptides like insulin and the GLP-1 medicines are regulated as drugs. (2) 'Safe because natural' — natural origin says nothing about dose, purity or effect, and these products have not passed the trials that establish safety. (3) 'They treat specific conditions' — the trial record is thin: a 2005 summary of a small BPC-157 trial in inflammatory bowel disease was called 'inadequate' by FDA reviewers, a knee-pain study reporting relief in 14 of 16 patients had no control group, and a 2025 review of BPC-157 for musculoskeletal injuries counseled caution. (4) 'Companies ignore them because they can't be patented' — hundreds of peptide patents sit in the USPTO database, and a patent on an early BPC-157 formulation is itself for sale. Stanford peptide scientist Katrin Svensson, whose lab works on peptides, summarized the gap: excitement is warranted; proof is not yet there.

What is Congress being asked to do?

WHRO's November 2, 2026 report describes two moves by Rep. Nancy Mace: language added to the House version of the annual defense policy bill that would keep the Defense Department from putting any legally available peptide on its banned-supplement list, and separate legislation ordering the Department of Veterans Affairs to study peptide therapies for veterans. The VA-study bill and the access bill are very different instruments — one generates evidence, the other pre-empts a safety list before the evidence exists — and coverage that blends them flatters the package. Institutional positions remain split: FDA scientists advised against expanding availability of the untested drugs; an FDA advisory committee endorsed the idea in July; the American Medical Association is leery of legalizing peptides that have not gone through traditional testing.

Why this watchdog page, on a mitochondria site?

Because one of the six peptides at the center of the federal debate — MOTS-c — is encoded in the mitochondrial genome, and mitochondrial language is doing marketing work across this market: 'cellular energy,' 'mitochondrial optimization,' 'root-cause repair.' Those phrases borrow the credibility of real mitochondrial biology for products whose human evidence, as the KFF analysis documents, consists of inadequate summaries and uncontrolled reports. The watchdog standard here is symmetric and simple: the same evidence labels this site applies to a Nature Communications mouse study apply to a clinic's peptide menu. Preliminary means preliminary, whoever is selling.

Where the evidence stands

• Established: None of the six peptides in the current federal compounding debate (BPC-157, Epitalon, KPV, MOTS-c, Semax, TB-500) is FDA-approved for safety or effectiveness; FDA scientists advised against expanding their availability; and compounded or 'research chemical' peptides have not passed standard clinical-trial requirements.
• Contested: The policy direction itself: an FDA advisory committee voted in July 2026 to endorse compounding access, HHS has published draft enforcement discretion (comments close November 13, 2026), and legislation reported November 2, 2026 would promote peptide access for troops and veterans — while the AMA remains leery and KFF Health News documents misleading sales claims and a thin trial record (an 'inadequate' BPC-157 IBD trial summary; an uncontrolled 16-patient knee-pain report).
• Absent: Adequate randomized human trial evidence for the marketed uses of these peptides, long-term safety data, and any FDA finding of efficacy for MOTS-c or the other five.